Ajanta Pharmaceuticals Ltd.
NSE: AJANTPHARMAjanta Pharmaceuticals Ltd.: A 30-second snapshot
Ajanta Pharma trades at ₹3506.2, up 35.75% over the past year and just 1.68% below its 52-week high, holding above both its 50-day (₹3259.37) and 200-day (₹2888.71) moving averages. Reported Q1 net profit rose 31% YoY to ₹334 crore, and the stock carries the highest quality score (60) among the 6 Pharma names listed in this peer set. A mean analyst rating of 1.57 is recorded across 14 analysts (1-5 scale, lower = more constructive).
P/E
38.6
Forward P/E
30.1
ROE
—
Debt / Equity
5.75
Profit Margin
+19.6%
Div. Yield
+1.8%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
74/100
News
6 headlines · 2 positive · 0 negative
Ajanta Pharma Q1 Profit Jumps 31% to ₹334 Cr - HDFC Sky
HDFC Sky
Ajanta Pharma Share Price: डिव्हिडंडमुळे शेअर पडला 3%, पण ही आहे खरी बातमी! - Whalesbook
Whalesbook
Hold Ajanta Pharma; target of Rs 3260: ICICI Securities - TradingView
TradingView
Buy Ajanta Pharma; target of Rs 3730: Prabhudas Lilladher - TradingView
TradingView
Ajanta Pharma షేర్ ధర పడిపోయింది.. కారణం ఇదే! - Whalesbook
Whalesbook
Recent context
- ·Q1 net profit reported up 31% YoY to ₹334 crore (HDFC Sky, 2026-07-30).
- ·Coverage in early August reported a share-price move of about 3% around a dividend declaration (Whalesbook, 2026-08-05).
- ·Two brokerage notes published in the same week carried price targets of ₹3260 (ICICI Securities, 2026-07-31) and ₹3730 (Prabhudas Lilladher, 2026-07-31), a spread of about 13% versus the ₹3506.2 current price.
Strengths
- +5-year earnings growth of 30.8% and revenue growth of 24.8%, with ROE above 15% in 4 of the last 5 years and positive free cash flow in 4 of 5 years (consistency score 77).
- +Q1 net profit reported up 31% YoY to ₹334 crore (HDFC Sky, 2026-07-30).
- +Highest quality score (60) among the 6 listed Pharma peers in this data set, ranking 1st of 6 on that metric.
- +Trades above both the 50-day (₹3259.37) and 200-day (₹2888.71) moving averages, up 35.75% over the trailing year and only 1.68% off the 52-week high.
Weaknesses
- −Debt-to-equity trend is classified as rising in the persistence data, even though the absolute multiple remains low at roughly 0.057x.
- −Current-period ROE is not populated in the fundamentals block; only the multi-year persistence figure (4 of 5 years above 15%) is available.
- −Sector peer comparison is limited: 1-year price-change data is missing for all 5 listed Pharma peers, and ROE is missing for 2 of them (Cipla, Sun Pharma).
- −Price sits about 1.7% below the closest identified resistance level (₹3566.13), with the nearest support 6.7% lower at ₹3271.03.
Open questions
- ?Does the rising debt-to-equity trend reflect capacity expansion, working-capital needs, or another driver, and how does it compare with the company's own multi-year trend line?
- ?How does the ~31% YoY profit growth reported for the quarter compare with the 30.8% five-year earnings growth trend — in line with, above, or below the recent trajectory?
- ?What assumptions might explain the analyst price targets ranging from ₹3260 to ₹3730 in the same week — differing views on margins, volumes, or valuation multiples?
- ?With price about 1.7% below the ₹3566.13 resistance level and only 1.68% off the 52-week high, what does recent volume behavior around that level suggest about supply and demand at current prices?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| AJANTPHARM | Ajanta Pharmaceuticals Ltd.You're viewing | 38.6 | — | 60 |
| Industry avg | across 5 peers | 47.9 | +14.9% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 65.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 70.5 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 30.3 | +8.8% | 4 |
Technical state
Current price
₹3,506.20
SMA 50
₹3,259.37
SMA 200
₹2,888.71
RSI (14)
61.8 (neutral)
From 52w high
-1.7%
1Y return
+35.8%
3M return
+8.6%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- lowDebt-to-equity trend is classified as "rising" in the persistence data, though the absolute multiple remains low at roughly 0.057x (raw fundamentals value of 5.747 is percent-scaled), so the direction of travel merits tracking rather than the level itself.
- lowCurrent-period ROE is not populated in the fundamentals key-metrics block; only the multi-year persistence measure is available, showing ROE above 15% in 4 of the last 5 years and positive free cash flow in 4 of 5 years (consistency score 77).
- low1-year price-change data is unavailable for all 5 listed Pharma peers (APOLLOHOSP, CIPLA, DRREDDY, MAXHEALTH, SUNPHARMA), and ROE is unavailable for 2 of them (CIPLA, SUNPHARMA), limiting relative-performance and profitability benchmarking within the sector table.
- lowCurrent price of ₹3506.2 sits about 1.7% below the nearest identified resistance level (₹3566.13) after a 35.75% one-year advance and a drawdown of just 1.68% from the 52-week high; nearest support is 6.7% lower at ₹3271.03.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 12 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 11 Aug 2026 · rotates through NIFTY 500 every ~5 days